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There is limited information on the prevalence of sexually transmitted infections and the prevalence of cervical neoplasia in rural
sub-Saharan Africa. This study describes the prevalence and the etiology of STIs and the prevalence of cervical neoplasia among
womeninsouthernMozambique.Anage-stratiﬁedcross-sectionalstudywasperformedwhere262womenaged14to61yearswere
recruited at the antenatal clinic (59%), the family-planning clinic (7%), and from the community (34%). At least one active STI
was diagnosed in 79% of women. Trichomonas vaginalis was present in 31% of all study participants. The prevalence of Neisseria
gonorrhea and Chlamydia trachomatis were 14% and 8%, respectively, and Syphilis was diagnosed in 12% of women. HPV DNA
wasdetectedin40%ofwomenandcervicalneoplasiawasdiagnosedin12%ofallwomen.Riskfactorsassociatedwiththepresence
ofsomeofthe STIswere being divorced orwidowed, having morethan onesexual partnerand having the partnerliving inanother
area. A higher prevalence was observed in the reproductive age group and some of the STIs were more frequently diagnosed in
pregnant women. STI control programs are a priority to reduce the STIs burden, including HIV and cervical neoplasia.
1.Introduction
Sexually transmitted infections (STIs) remain a major
public health problem in developing countries [1–5]. The
HIV/AIDS pandemia [6] has increased the awareness about
other STIs. However, their true scope and impact are still
mostly unknown. Most of the burden of STIs is borne by
women, yet women are less likely than men to seek treatment
forSTIs[7,8].Indevelopingcountries,complicationsrelated
to STIs are a major cause of mother and child mortality and
morbidity during pregnancy [9–11] as well as to the high
incidences of cervical cancer [12, 13]. Previous data from
Mozambique [14–16] shows alarmingly high incidences of
cervical cancer and congenital syphilis which suggests that
STIs prevalence is likely to be high. In the context of a steady
increase of HIV prevalence [17] and in an era where access
to health care and prevention systems are still weak in most
parts of sub-Saharan Africa, further information to guide
eﬀective STIs prevention strategies as well as diagnostic and
management policies is needed.2 Infectious Diseases in Obstetrics and Gynecology
Accordingly, a descriptive study on the prevalence and
risk factors for STIs and cervical neoplasia among women
living in rural Mozambique was carried out in order to
contribute to generate further information.
2. Methods
2.1. Study Area and Population. T h es t u d yt o o kp l a c ei nt h e
Manhic ¸a District, southern Mozambique, where the Centro
de Investigac ¸˜ ao em Sa´ u d ed eM a n h i c ¸a (CISM) is located and
approximately at 80Km from the capital, Maputo.
The population in the Manhic ¸a District lives in a
semi-urban and rural setting and crop farming is the
main activity in the area. Illiteracy is prevalent, being
24% among men and 47% among women. While 66%
of men and 49% of women have had primary education,
only 9% of men and 4% of women have had secondary
education, and less than 1% of both men and women have
gone beyond their secondary education [18]. An ongoing
demographic surveillance system, that has been described
in detail elsewhere is in place, covering a population of
around 82,000 inhabitants, at the time of the study it covered
a population of 36.000. Population data is collected on a
semestral basis with a biannual census of the population
[19].
The population structure is similar to that of many
developing countries with 54% of the population being less
than 20 years old.
The adjacent Manhic ¸a District Hospital (MDH) is a 110-
bed health facility with antenatal care clinic (ANC) services
as well as a family planning clinic.
Atthetimewhenthestudywascarriedout,screeningand
treatment for syphilis were provided at the ANC. Residents
are mostly subsistence farmers or employees in a nearby
sugar cane processing factory. A high number of the adult
male population of the area migrates to South Africa to
work at the mines and many other move to the capital of
Mozambique for job purposes as well.
2.2. Study Design. This is a cross-sectional, age-stratiﬁed
study of STIs and cervical neoplasia in women. Two hundred
and sixty two women aged 14–61 were recruited between
August and October 2000. Fifty-nine percent were enrolled
at the ANC and 7% at the family planning clinic (FPC)
of the MDH. The remaining 34% were randomly selected
from the community using the DSS census from the older
than 50-year-old female population. Women recruited at
the community were invited by the ﬁeld workers to the
hospital to complete the study visit. Attendance to the
ANC is high and it is estimated that approximately 90%
of pregnant women are visited at least once at the ANC.
Women were oﬀered an informed consent and no study
procedures were performed before acceptance to the study
was given by either signing or thumb printing the document.
The refusal rate to participate in the study was 5%. The
inclusion criteria were to attend the ANC or the FPC
and for the community participants to be in the list
randomly produced from the census. Exclusion criteria were
exclusively their refusal to sign the informed consent. The
study visit consisted of a gynecological exam, collection of
cervicalsamples,and5mLofbloodbyvenipuncture.During
the visit, relevant information regarding the participant
education, socioeconomic status (see Table 1), reproduc-
tive history and lifetime sexual behavior was collected as
well. In accordance with the Ministry of Health (MOH)
guidelines, unlinked HIV testing was done anonymously
since, at the time of the study, there were no voluntary
counseling and testing services, nor were antiretroviral
drugs available. Women did not receive STIs presumptive
treatment and they were oﬀered free treatment according
to national guidelines if diagnosed with an active treatable
STI.
Women with a Pap smear compatible with cervical
intraepithelial dysplasia/neoplasia (CIN) or carcinoma were
referred for histological conﬁrmation and appropriate clini-
cal management to the Maputo Central Hospital.
2.3. Laboratory Methods. The rapid plasma reagin (RPR,
Syphacard, Wellcome, USA) test was used for syphilis
diagnosis and results were conﬁrmed using an enzyme
immunoassay (CAPTIA Syphilis-G, Trinity Biotech, Dublin,
Ireland). CT DNA was detected on cervical samples by
the CT-ID assay (Digene Corporation, Silver Spring, MD,
USA). Neisseria gonorrhea (NG) was identiﬁed by Gram
stain and culture (Thayer-Martin, Bethesda, MD, USA) of
the cervical mucosa. Trichomonas vaginalis was detected
by direct microscopic examination of went-mount prepa-
rations of the vaginal discharge. Anti HSV-2 antibodies
were determined using an ELISA kit from MRL Diag-
nostics (Cypress, CA, USA). Anti HIV antibodies were
detected by Imx HIV-1/HIV-2 III Plus EIA (Abbot Diag-
nostics, IL, USA). Antibodies against Hepatitis B virus
(anti-HBc) and HBsAg were detected using the ELISA
technique ETI-AB-COREK-2 and ETI-MAK-3 (DiaSorin).
HPV DNA was determined from a cervical swab by
the reverse line-blot (RLB) strip-based detection system
[20–22] and further improved by using the PGMY09-
PGMY11primersystem.Cervicalsmearswereprocessedand
read following standard procedures. Antibiotic sensitivity
was assessed by standard techniques using disc diﬀusion
methods and interpreted according to the NCCLS criteria
(National Committee for Clinical Laboratory Standards,
2000).
2.4. Statistical Methods and Deﬁnitions. Syphilis infection
was deﬁned as a RPR positive test conﬁrmed by ELISA for
T. Pallidum IgG antibodies. The variable “any treatable STI”
was created for women with at least one of the following:
syphilis, gonoccocal infection, Trichomonas vaginalis or CT.
T h ev a r i a b l e“ a n ya c t i v eS T I ”i n c l u d e dw o m e nw i t ha n yo f
the following: syphilis, gonoccocal infection, Trichomonas
vaginalis, CT, HPV or HIV infection. HSV was not included
in this latter group because no conﬁrmation of active
disease laboratory analysis was performed during the study.
Percentages were compared by the uncorrected χ2 test and
the Fisher’s exact test. Odds ratio (OR), and 95% ConﬁdenceInfectious Diseases in Obstetrics and Gynecology 3








Ethnic group Shangana 208 79
Other 54 21
Education Reads and/or writes 81 31
Neither reads nor writes 181 69
Marital status
Never married 20 8
Currently married 212 81
Divorced or widowed 30 11
Number of women living with husband
1 185 71






Manual worker 44 17
Shop keeper 7 3
Civil servant 10 4
Other 45 17
Unknown 38 15
Husband’s place of residence
Manhic ¸a 133 51
Maputo 27 10




12 9 1 1
2 to 5 99 38
>58 5 3 2
Unknown 3 1
Pregnant now No 111 42
Yes 151 58





Number of sexual partners in lifetime




Intervals (CI) were estimated by logistic regression models.
Adjustments for age and ethnic group were performed in
the multivariate models. Age was categorized in tertiles (14–
26, 27–42, and 43–61) for the analysis of risk factors to
allow for small numbers or absence of cases in some of the
outcomes.
Multivariate models for STs and cervical neoplasia were
estimated using a forward-stepwise procedure, with 0.05
from the Likelihood-ratio test as signiﬁcance level for
addition to the model. Potential independent variables for
such models were the participant education, socioeconomic
status, reproductive history and lifetime sexual behavior as
well as other coinfections (STIs other than the one used as
dependent variable for each model). Age and ethnic group
were forced to be part of all multivariate models in order to
adjust for them.4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Prevalence of STIs and cervical neoplasia in women from Manhic ¸a, Mozambique.
n/total Prevalence (%) 95% Conﬁdence interval
Gonococcal infection 34/250 14 (10; 19)
Syphilis (RPR & IgG) 31/258 12 (8; 17)
HPV DNA 100/253 40 (33; 46)
HIV antibodies 30/256 12 (8; 16)
HSV-2 antibodies 213/257 83 (78; 87)
Chlamydia trachomatis 19/253 8 (5; 11)
Trichomona vaginalis 78/254 31 (25; 37)
HBsAg antibodies 20/255 8 (5; 12)
Anti-HBc antibodies 160/256 63 (56; 68)
Any treatable STI∗ 128/252 51 (44; 57)
Any active STI∗∗ 179/254 70 (64; 76)
Cervical neoplasia 30/245 12 (8; 17)
∗Any treatable STI: syphilis (RPR conﬁrmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
∗∗Any active STI: syphilis (RPR conﬁrmed by IgG), gonococcal infection, trichomona vaginalis, chlamydia trachomatis, HPV or HIV infection.
The conﬁdence intervals for the proportion of STIs in
Table 2 were calculated by the Exact (or Clopper-Pearson)
method, based on the binomial distribution.
TheanalysiswasperformedusingSTATAsoftware(Stata,
East College Station, TX, USA).
3. Results
3.1. Demographic Characteristics. The median age at ﬁrst
sexual intercourse was 16, and 43% initiated sexual inter-
course at age 15 years or younger (Table 1). About 11% of
women had been married more than once and a third of
their husbands had previously lived with 2 or more diﬀerent
women. The husbands were, on average, 5 years older than
their wives (data not shown).
Women recruited at the FPC had a higher literacy
level (47% versus 30% and 15% from the ANC and the
community, resp.; P ≤ .001), and had more than one sexual
partner in a higher percentage in comparison to the other
groups (58% versus 41% and 33% from the ANC and the
community, resp.; P = .047).
3.2. Prevalence of STIs and Cervical Neoplasia. Vaginal
discharge was observed in 68% of cases, cervical mucous in
3 5 % ,a n o g e n i t a lw a r t si n5 % .O v e r a l lp r e v a l e n c eo fS T I si s
shown in Table 2.
Nearly 70% (179/254) of all women and 75% (112/148)
of pregnant women had at least one active STI. This
prevalence reached 82% in the 14–20 years age group, and
decreased signiﬁcantly with age, dropping to 44% in the old-
est group (51–61 years). Over half (51%) of the participants
had at least one treatable STIs. We deﬁned treatable taking
into account what was available for treatment as per national
policy guidelines at the time of the study.
ThemostcommonSTIwasTrichomonasvaginalisfound
in 31% of women.
The overall prevalence of gonoccocal infection was 14%
(34/250). It was 19% (27/145) in pregnant women and 33%
(6/18) among women attending the FPC. Prevalence was
associated with age (P<. 001), being more prevalent in the
younger age group. Antimicrobial sensitivity of the NG was
61% for erythromycin, 18% for penicillin and ampicillin,
15% for chloramphenicol, 9% for gentamicin and 3% for
cotrimoxazol. Sensitivity to ceftriaxone, spectinomycin and
azythromycin was not assessed. CT DNA was detected in
7.5% (19/253) of cervical samples. The prevalence was
lower in the 41–61 age group, but there was no statistically
signiﬁcant association with age. Among pregnant women,
the prevalence was 10% (15/151). Thirty-nine women had a
RPR positive test (15%), of which 31 (75%) were conﬁrmed
byEIA,givinganoverallsyphilisprevalenceof12%(31/258).
The prevalence increased with age, but this relationship was
not statistically signiﬁcant (P = .67). Among pregnant
women, syphilis prevalence was 10% (15/149). Overall
prevalence of IgG antibodies against Tp a l l i d u mwas 39%
(100/257), increasing signiﬁcantly with age (P<. 001).
Overall seroprevalence of HIV was 12% (30/256) and 21%
(4/19) among women attending the FPC. The highest
prevalence was found in the 31–50 age group (15%; 16/104),
buttherewasnosigniﬁcantrelationshipwithage.Anti-HSV-
2 antibodies were found in 83% (213/257) of all participants.
This frequency increased signiﬁcantly with age (test for trend
P<. 001). The lowest prevalence (56%; 28/50) was in the
youngest age group. HBsAg was detected in 8% (20/255)
and anti-HBc in 62.5% (160/256) of women, respectively.
The overall prevalence of HPV DNA was 40% (100/253), the
highest was in the youngest age group (test for trend P<
.001), and decreased with age (see Figure 1). HPV genotypes
have been already published [23] Cervical neoplasia was
detected in 30 women (12.2%): 5.3% (13/245) with LSIL
(low-grade squamous intraepithelial lesions that include
CIN I), 6.5% (16/245) with HSIL (high-grade squamous
intraepithelial lesions that include CIN II and III), and one
woman (0.4%) with carcinoma.
3.3. Sociodemographic, Behavioral Risk Factors and STIs Coin-




















































Figure 1: Seroprevalence of syphilis, HIV and HSV-2 (a) and prevalence of gonococcal, HPV, trichomonal and chlamydia trachomatis (CT)
infections (b).
sociodemographic and sexual behavior-related risk factors
f o re a c hS T Ia n dc e r v i c a ln e o p l a s i a .
Reporting more than one lifetime sexual partner was
the only factor statistically signiﬁcant related to cervical
gonoccocal infection. Observation of vaginal secretion or
cervicalmucousduringclinicalexamwasnotassociatedwith
gonoccocalinfection.Thenumberoflifetimesexualpartners
and the marital status were signiﬁcantly associated with the
diagnosis of syphilis, and the presence of HPV DNA was
associatedwithanearlythree-foldhigherrisk(OR=3.2;95%
CI 1.4, 7.5). Abnormal cervical cytology was associated with
HPV DNA detection in cervical cells (OR = 10.1; 95% CI 3.7,
27.5). The presence of anogenital warts was also related to
HPV infection (OR = 4.2; 95% CI 1.0, 17.8). A positive test
for syphilis was associated with HPV DNA detection (OR =
4.1; 95% CI 1.9, 9.1). In the adjusted analysis, being divorced
or widowed was signiﬁcantly associated with HIV infection.
HIVseropositivityprevalencerosewithincreasingseverityof
cervical abnormalities: 9% in women with normal cytology,
16% in women with ASCUS, 17% in women with LSIL,
and 19% in women with HSIL, and the only woman with
carcinoma (test for trend P = .02). HIV seropositive women
weremorelikelytohaveHPVDNAdetectedintheircervices,
but the diﬀerences were not statistically signiﬁcant (47%
versus 37%; OR = 1.6; 95% CI 0.5, 3.5). CT infection was
not signiﬁcantly associated with any social or behavioral risk
factor. No relationship between detection of this infection
andeithervaginalsecretionorcervicalmucouswasidentiﬁed
in the multivariate analysis.
3.4. STIs Risk by HIV Status. Except for HBsAg, there was
a consistent association trend for the presence of f all STIs
in HIV positive women. However, only CT DNA detection
and presence of cervical abnormalities reached borderline
statistical signiﬁcance (Table 4).
4. Discussion
Although none of the participants were selected based
on their STIs seeking behavior, 70% and 50% of women
presented with at least one active or treatable STI. It is
generally assumed that STI prevalence is higher in urban
residents [24]. However, these ﬁndings show that the burden
of STIs in rural areas may be underestimated. The STI
prevalences found were higher than those reported from
other rural areas in sub-Saharan Africa [25, 26]. The high
migration rate might partially explain the high frequency of
STIs in these women [4].
Vaginal discharge showed no correlation with the pres-
ence of infection, which suggests that syndromic manage-
ment alone is unlikely to have a major public health impact
incontrollingSTIsandHIVtransmissioninwomen[27–29].
On the contrary, the presence of anogenital warts was
signiﬁcally correlated with the presence of any treatable
STI. Most pregnant women had either an active (75.6%)
or treatable (55%) STI. These frequencies were higher
than what has been reported in the region [7, 30]a n d
in a urban area of northern Mozambique (51%) [31].
The most frequent STI was Trichomonas vaginalis which
was found in 31% of women, and taking into account
that the direct examination only detects approximately a
60%–70% of infections it is reasonable to assume that we
are underestimating its prevalence. The high prevalence
of gonorrhea, CT, and syphilis are particularly alarming
due to their potential impact on the newborn. At the
time of the study, the only control program in place was
that of syphilis prevention. These results call for diﬀerent
approaches to STIs prevention of the main STIs in both
pregnant women and their partners. In Mozambique, cur-
rent guidelines recommend ciproﬂoxacin in cases of vaginal
discharge [32]. However, this drug is rarely available and
kanamycin plus erythromycin is the combination still most
frequently used. Sensitivity for kanamycin was not tested
but it can be assumed to be similar to that of gentamicin
(9%), which may partly explain the high frequency of
gonoccocal infection observed. These are still the only
available results on NG sensitivity in the country, and reﬂect
the diﬃculties that countries with limited resources face in
reconciling their health policies with some recommenda-
tions.6 Infectious Diseases in Obstetrics and Gynecology
Table 3: Signiﬁcant variables according to the multivariate analysis of risk factors for STIs and cervical neoplasia.
Infection Variable Multivariate OR∗ (95% CI) P-value∗∗
Gonococcal infection Number of sexual partners 11 .014
>1 2.8 (1.2; 6.2)
Syphilis (RPR & IgG) HPV No 1 .005
Yes 3.2 (1.4; 7.5)
Syphilis (RPR & IgG) Marital status
Never married 1
.005 Married now 0.7 (0.1; 3.9)
Divorced or widowed 3.6 (0.6; 21.9)
HPV Cervical neoplasia
No 1
<.0001 Yes 9.8 (3.7; 26.3)
Unknown 2.7 (0.6; 12.0)
HPV RPR No 1 <.0001
Yes 4.1 (1.9; 9.1)
HPV Anogenital warts No 1 .054
Yes 4.2 (1.0; 17.8)
HIV Marital status
Never married 1
.005 Married now 0.5 (0.1; 2.3)
Divorced or widowed 2.7 (0.5; 16.0)
HIV Parity
None 1
.02 1 child 0.7 (0.1; 3.6)
2 to 5 0.6 (0.1; 3.0)
more than 5 4.3 (0.7; 26.9)
HSV-2 Age at ﬁrst child
Never had 1
.014
13–18 3.7 (1.1; 12.9)
19 48.7 (3.0; 792.7)
20–28 27.3 (3.1; 241.2)
Unknown 2.3 (0.5; 9.7)
HSV-2 Selection of women
Antenatal clinic 1
.006 Family planning 0.1 (0.0; 0.8)
Other 0 (0.0; 0.3)
Trichomona vaginalis Husband’s place of residence
Manhic ¸a 1
.002 Maputo 2.5 (1.0; 6.3)
South Africa 1.2 (0.6; 2.4)
Unknown 0.2 (0.1; 0.6)
Trichomona vaginalis Anogenital warts No 1 .018
Yes 7.1 (1.4; 36.5)
HBsAg Number of women living with husband 11 .028
>1 0.1 (0.0; 0.8)
Any treatable STI# Anogenital warts No 1 .007
Yes 11 (1.9; 63.1)
Any active STI## HSV-2 antibodies No 1 .0029
Yes 2.4 (1.1; 5.4)
Any active STI## Chlamydia trachomatis No 1 .042
Yes 2.3 (1.0; 5.1)
Cervical neoplasia HPV No 1 <.0001
Yes 10.1 (3.7; 27.5)
Cervical neoplasia RPR No 1 .068
Yes 0.2 (0.1; 1.1)
∗Adjusted by age and ethnic group.
∗∗Likelihood Ratio Test versus model with variable removed.
#Any treatable STI: syphilis (RPR conﬁrmed by IgG), gonococcal infection, trichomona vaginalis or Chlamydia trachomatis.
##Any active STI: syphilis (RPR conﬁrmed by IgG), gonococcal infection, trichomona vaginalis, Chlamydia trachomatis, HPV or HIV infection.Infectious Diseases in Obstetrics and Gynecology 7
Table 4: Prevalence and risk of STIs and cervical neoplasia by HIV status.
STD by HIV
HIV (−)H I V ( + )
Adjusted∗ OR 95% Cl P N = 226 N = 30
n % n %
Gonococcal infection 27 12 6 20 1.9 (0.7; 5.5) .219
Syphilis (RPR & IgG) 26 12 5 17 1.6 (0.5; 4.5) .408
HPV DNA 83 37 14 47 1.6 (0.7; 3.5) .262
HSV-2 antibodies 185 82 27 90 2.1 (0.6; 7.6) .259
Chlamydia trachomatis DNA 14 6 5 17 3.1 (1.0; 9.6) .051
Trichomona vaginalis 67 30 9 30 1.0 (0.4; 2.4) .966
HBsAg anribodies 19 8 1 3 0.4 (0.1; 3.0) .359
Anti-HBc antibodies 137 61 22 73 1.8 (0.8; 4.3) .172
Any treatable STI∗∗ 107 47 18 60 1.7 (0.8; 3.8) .190
Cervical neoplasia 23 10 6 20 2.5 (0.9; 7.0) .088
∗Adjusted by age and ethnic group.
∗∗Any treatable STI: syphilis (RPR conﬁrmed by IgG), gonococcal infection, trichomona vaginalis or chlamydia trachomatis.
CT infection prevalence was 8% overall and the 14–20
years old group had a higher prevalence of CT infection
(10%) than that reported from rural Tanzania (2.4% of
female adolescents) [33]. This discrepancy may be explained
by the recruitment sources of our study being more likely
for our participants to have had more sexual partners. These
data are consistent with the evidence that girls and young
women are more susceptible to CT infection than older
women,withtheconsequentrisk,amongothers,ofinfertility
[34].
Syphilis prevalence between 1.6% and 9.8% in rural
areas [16] to 18.3% in Maputo has been reported among
women in Mozambique [11]. In this study, syphilis was
detected in 12% of all women and in 10% in the youngest
age group. These ﬁgures are also higher than those from
rural areas of South Africa (8%) [8] and Tanzania (9.1% of
all women, 6.6% of adolescents) [35]. Again, the diﬀerent
selection of individuals may explain the diﬀerent rates found
in the current study. However, syphilis prevalence was also
high in the oldest age groups, where most women were
recruited from the community and therefore not exposed to
the potential selection bias.
The overall prevalence of HSV-2 antibodies was high
(83%). Among 14–20 year old women the prevalence was
56%, higher than that reported in another study from rural
Africa (27%) [36]. HSV-2 is of much interest in Africa
because it increases the risk of HIV transmission [37].
Although the information on HSV-2 is based on seropreva-
lence of antibodies, HSV-2 seropositivity has been proposed
as a marker of sexual risk behavior among adolescents [36].
These observations support the latter, and suggest that there
is high-risk sexual behavior at very young ages.
The overall prevalence of HPV infection was high,
especially in the youngest age group where over 50% were
infected. HIV and co infection with other STIs are highly
prevalentinthispopulation,andthisisknowntoincreasethe
risk of progression from cervical HPV infection to cervical
neoplasia and invasive cancer [38]. The HIV seroprevalence
(12%) found was still lower than that reported from other
areas of Southern Africa [39]. However, it could be foreseen
that with this high STIs burden, the epidemic could rise
dramatically if no eﬀective STIs prevention is implemented.
HIV prevalence estimates among ANC attendees in this
area have reached 24% conﬁrming this suspicion [40]. The
risk factors for STI detection identiﬁed are consistent with
those observed in other studies [41]. However, the indirect
informationobtainedthroughquestionnairesmakesthedata
on behavioral risk factors subject to bias and diﬃcult to
reproduce [42, 43]. The main limitation of this study is that
many women were not selected from the community and
that the size and age distribution of the three recruitment
sources are not comparable. These may limit the extrapola-
tionoftheseﬁndingstothegeneralpopulation.However,the
similar rate of syphilis found among the community-based
recruited women suggests that the potential selection bias
may not be relevant.
Our data is still to date the only available information on
the prevalence of STIs and cervical cancer among women
in Mozambique. A study performed in 2004 in an urban
area of Mozambique reported a remarkable decline in STIs,
which was attributed to successful implementation of STIs
prevention strategies in that area [31].
We have to mention that one of the limitations of the
study is that it may be underpowered for some of the tested
associations.
In conclusion, the burden of disease associated with STIs
borne by African women in rural areas, and the implications
for the acquisition and transmission of HIV and cervical
neoplasia, are enormous. Reproductive health programs do
not easily reach adolescents and older women, so speciﬁc
approaches to target them should be envisioned and imple-
mented. In pregnant women, there is a need for a more
aggressive approach to avoid the harmful eﬀects associated
with STIs on mothers and children. For HPV infections and
cervical cancer, recent development of vaccines [44]o ﬀers
great hope, but the challenge is that they become aﬀordable
for developing countries. There is an urgent need to develop
interventions in order to avoid the burden of morbidity
due to STIs and the further spread of HIV in rural African
populations.8 Infectious Diseases in Obstetrics and Gynecology
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